KIDNEY INT:炎症和高水平的FGF23是CKD患者死亡的独立危险因素!

2016-12-24 haofan MedSci原创

因此,白细胞介素-6、C反应蛋白水平和FGF23升高是CKD患者死亡的独立危险因素。

炎症是慢性肾脏疾病(CKD)的一种后果,并与许多临床不良预后有关。炎症可以刺激成纤维细胞生长因子23(FGF23)产生,高水平的FGF23与CKD患者死亡率独立相关。几个大型的前瞻性研究探讨了炎症和CKD患者死亡率的关系,但并没有评估炎症、FGF23和CKD患者死亡风险之间的相互关系。

近日,肾脏病领域权威杂志kidney international上发表了一篇研究文章,研究人员在3875名参与者中进行了一项前瞻性调查,这些参与者患有2-4期CKD,均来自评估基础血浆白细胞介素-6、高敏C反应蛋白和FGF23水平与全因死亡率之间相关性的慢性肾功能不全队列(CRIC)研究,在终末期肾脏疾病的发病进行审查。

在平均6.9年的随访中,在终末期肾脏疾病发病之前有550人死亡(20.5/1000人/年)。独立的多变量调整后分析,研究者发现高水平的白细胞介素-6(自然对数变换后的水平每增加一个标准差的危险比)为1.35(95%可信区间为1.25−1.46),C-反应蛋白为1.28(1.16−1.40)和FGF23为1.45(1.32−1.60)分别与死亡风险增加独立相关。对FGF23进行进一步的调整,与IL-6和C反应蛋白相关的死亡风险是减弱程度最小。相比于炎症和FGF23水平位于最低四分位数范围的参与者,那些位于最高四分位数范围的参与者多变量调整后的死亡风险比对于白细胞介素-6和FGF23为4.38(2.65–7.23),对于C-反应蛋白和FGF23则为5.54(3.04–10.09)。

因此,白细胞介素-6、C反应蛋白水平和FGF23升高是CKD患者死亡的独立危险因素。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2016-12-26 gwc389
  6. [GetPortalCommentsPageByObjectIdResponse(id=2037175, encodeId=9ddc203e175ed, content=<a href='/topic/show?id=9be468126d4' target=_blank style='color:#2F92EE;'>#独立危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68126, encryptionId=9be468126d4, topicName=独立危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Oct 11 20:45:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1956605, encodeId=44f6195660540, content=<a href='/topic/show?id=e15ce3940f' target=_blank style='color:#2F92EE;'>#FGF23#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7394, encryptionId=e15ce3940f, topicName=FGF23)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/JicbM9ddhTaNkKdhKQ8adCYWzVJQKZXsqSTg3ia12tmdibiaoTZTEjBqfVvmfODz1KpD73pKy4h1W0fAXj62kxGbQA/132, createdBy=d2132500095, createdName=ms5768352621950538, createdTime=Tue Aug 01 04:45:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768831, encodeId=feb51e68831eb, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Fri Jan 27 14:45:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983494, encodeId=4ac91983494db, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Mar 22 05:45:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602984, encodeId=9fab1602984a3, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Dec 26 01:45:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=165598, encodeId=61831655986d, content=很受用,以后临床用得到, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Dec 25 14:03:26 CST 2016, time=2016-12-25, status=1, ipAttribution=)]
    2016-12-25 虈亣靌

    很受用,以后临床用得到

    0

相关资讯

炎症与感染之间,你划过等号吗?

炎症就是具有血管系统的活体组织对损伤因子所发生的以防御为主的局部组织反应。炎症局部的基本病变是变质、渗出和增生,其中变质是损伤,渗出和增生是抗损伤。炎症过程就是一个损伤、抗损伤和修复三为一体的较量过程。从上面概念中我们知道,炎症需要在损伤因子的作用下才可以发生,那么有哪些因子可以导致炎症呢?① 微生物引起的炎症细菌、病毒、立克次体、支原体、真菌、螺旋体和寄生虫等为炎症最常见的原因。② 物理性因子引

Science子刊:对抗炎症和疼痛的新武器——纳米抗体

近日,来自德国汉堡大学医学中心的一项研究发表了一种称为纳米抗体(nanobody)或微型抗体(miniantibodies)的新型生物分子,它可以阻断炎症并减轻小鼠的疼痛,研究人员认为这种技术可能成为针对炎症性疾病治疗的新策略。这项研究发表于11月23日的Science Translational Medicine杂志上。在小鼠实验中,纳米抗体似乎比常规抗体或常用的抗炎药在控制炎症方面更有效。研究

PNAS:五个关键因子——癌症免疫疗法的瓶颈

导语:免疫检查点阻断为何无法对所有癌症患者有效?约翰霍普金斯大学的科学家们则分析了包括癌症基因图谱TCGA中九种癌症类型的3,500份肿瘤样本,检测肿瘤中五种生物标记物的免疫活性。虽然许多癌症患者对目前流行的癌症免疫疗法药物,如nivolumab 和 pembrolizumab都能产生积极的应答,但这并不是绝大多数。一般认为其中一些治疗失败是由于所谓的“冷”肿瘤,也就是说不会出现T细胞浸润,缺乏T

《柳叶刀》子刊:你所不知的“天才病”,与体内炎症有关

导语:从《独立宣言》起草者杰弗逊到英国女作家伍尔芙,从梵高、玛丽莲·梦露、费雯丽到丘吉尔……这些名人都是双相障碍患者,因此,也有人称双相障碍为“天才病”。近日发表在《柳叶刀》子刊的研究揭示,一种炎症的生物标志物CRP的水平与双相障碍程度成正比。你所不知的“天才病”——双相障碍双相情感障碍(Bipolar Disorder,也称双相障碍)在发病时会表现出躁狂和抑郁两种发作症状,甚至会出现躁狂、抑郁反

NAT COMMUN:华东师大发现糖尿病人伤口难愈合新机制

导语:华东师范大学生命科学院赖玉平课题组揭示了糖尿病伤口难愈合的新机制,为糖尿病伤口愈合的临床治疗提供了新靶点和新方法。相关成果日前在线发表于《自然—通讯》杂志。华东师范大学生命科学院赖玉平课题组揭示了糖尿病伤口难愈合的新机制,为糖尿病伤口愈合的临床治疗提供了新靶点和新方法。相关成果日前在线发表于《自然—通讯》杂志。糖尿病伤口不愈合(糖尿病足)是糖尿病患者的主要并发症之一,会导致患者面临截肢危险。

两岸三地学者共同在《Nature》发文,称发现动脉粥样硬化形成新机制

近日,天津医科大学、香港中文大学生物医学学院和台湾细胞及系统医学研究所合作完成的一项研究发现一种名为YAP/TAZ的血管内皮细胞转录调控因子与动脉粥样硬化形成及血管炎症有密切关系。 这一结果发表在《Nature》上。血管内皮细胞是形成血管内壁表面的细胞层,而YAP/TAZ是这种细胞的转录调控因子,YAP/TAZ本身被视为“癌基因”,会促进癌症的发生及发展。而本研究发现,抑制YAP/TAZ活性还有助